𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-Term Electrical Inhibition of Deep Brain Targets in Movement Disorders

✍ Scribed by A. L. Benabid; A. Benazzouz; D. Hoffmann; P. Limousin; P. Krack; P. Pollak


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
582 KB
Volume
13
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Stimulation of the thalamic nucleus ventralis intermedius (Vim) at high (130-Hz) frequency has been used over the last 8 years as a treatment in 134 patients with movement disorders (91 Parkinson's disease [PD], 23 essential tremor [ET], 21 various dyskinesias and dystonias, including four multiple sclerosis [MS]), implanted with long-term electrodes connected to a programmable stimulator. In PD patients, tremor was selectively suppressed for < or = 11 years. In ET patients, results were satisfactory, but in 35% of the cases deteriorated with time, when tremor had an action component. Other types of dyskinesias were much less influenced. Sixty-eight patients were bilaterally implanted, and 14 were implanted contralateral to a previous thalamotomy. Side effects were often minor, well tolerated, and immediately reversible. Three secondary scalp infections led to temporary removal of implanted material. There was no permanent morbidity. Long-term Vim stimulation, which is reversible, adaptable, and well tolerated, even by bilaterally operated-on (68 of 134) and by elderly patients, should replace thalamotomy in the regular surgical treatment of parkinsonian and essential tremors. More recently, we stimulated the subthalamic nucleus (STN) in 51 patients (44 bilateral) and the globus pallidus internus (GPi) in 12 patients (seven bilateral). STN stimulation has a spectacular effect on akinesia and rigidity and may improve the patients so as to maintain them all day at a level similar to their best "on" periods. A 30-50% reduction in drug dosage was possible in most of the patients. GPi stimulation has indications and effects similar to those of pallidectomy: abnormal involuntary movements are totally suppressed, whereas effects on akinesia and rigidity are not so important as they are with STN stimulation. For all three targets, morbidity is low and reversible, even when bilateral implantations are performed. The deep-brain stimulation method has now proved its safety as compared with ablative surgery and is able to provide a significant improvement to these severely disabled patients. Long-term follow up is establishing the security of the method, which should be considered in earlier stages of the disease actively to participate to rehabilitation.


πŸ“œ SIMILAR VOLUMES


Long-term tolerability of tetrabenazine
✍ Christopher Kenney; Christine Hunter; Joseph Jankovic πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 90 KB πŸ‘ 1 views

## Abstract We sought to review the long‐term tolerability of tetrabenazine (TBZ) and seek determinants of tolerability in the treatment of hyperkinetic movement disorders. A retrospective chart review was performed on patients treated with TBZ between 1997 and 2004. Efficacy of TBZ was assessed by

Long-term safety and efficacy of unilate
✍ William C. Koller; Kelly E. Lyons; Steven B. Wilkinson; Alexander I. Troster; Ra πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 64 KB πŸ‘ 1 views

## Abstract Our objective was to investigate the long‐term safety and efficacy of unilateral deep brain stimulation (DBS) of the VIM nucleus of the thalamus in essential tremor. Forty‐nine patients were evaluated for DBS between December 1993 and March 1998. Tremor was assessed by a clinical rating

Long-term efficacy of botulinum toxin A
✍ G-Y.R. Hsiung; S.K. Das; R. Ranawaya; A.-L. Lafontaine; O. Suchowersky πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 780 KB

Although botulinum toxin A (BTX) has been licensed in Canada for treatment of various movement disorders since 1990, few clinical studies regarding its long-term efficacy and side effects have been reported. We conducted a retrospective analysis of 235 patients who received BTX from our movement dis